Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 31-year-old woman is evaluated in the neurology clinic to discuss escalating her disease-modifying therapy. She has a 4-year history of relapsing-remitting multiple sclerosis. Despite strict adherence to glatiramer acetate, she has experienced three distinct clinical relapses over the past year. A recent magnetic resonance imaging (MRI) scan of the brain and cervical spine reveals multiple new T2-hyperintense and gadolinium-enhancing lesions. The physician decides to transition her to oral fingolimod. She has a remote history of an appendectomy but is otherwise healthy. Vital signs are normal. Which of the following baseline assessments and initiation protocols are strictly required to ensure the safe administration of this specific medication? (Select exactly 2 options)

  1. Baseline electrocardiogram and continuous cardiovascular monitoring for at least 6 hours after the initial doseCevap
  2. Comprehensive ophthalmologic evaluation, including a focused examination of the maculaCevap
  3. C
    Assessment of anti-JC virus (JCV) antibody status to evaluate the risk of progressive multifocal leukoencephalopathy
  4. D
    Transthoracic echocardiography to rule out underlying structural heart disease and assess left ventricular ejection fraction
  5. E
    Lumbar puncture with cerebrospinal fluid analysis to quantify baseline oligoclonal bands

Cevap

The correct requirements are a baseline electrocardiogram with 6-hour cardiovascular monitoring after the initial dose, and a comprehensive ophthalmologic evaluation to examine the macula.
Fingolimod acts as a sphingosine 1-phosphate (S1P) receptor modulator. While it effectively traps lymphocytes in lymph nodes to prevent central nervous system inflammation, these receptors are also present in the heart and eyes. Initial dosing acts as a cardiac agonist, causing a transient but potentially severe decrease in heart rate and atrioventricular conduction. Thus, a baseline electrocardiogram and a 6-hour first-dose observation period are required. Furthermore, S1P modulation increases vascular permeability, establishing a known risk for fingolimod-associated macular edema (FAME), which mandates baseline and follow-up ophthalmologic screening.

Adım Adım Çözüm

1
Identify the primary mechanism of action of the planned pharmacotherapy.
Fingolimod is a sphingosine 1-phosphate (S1P) receptor modulator.
Understanding the receptor targets explains the systemic side effect profile beyond the central nervous system.
2
Correlate S1P receptor locations with required monitoring parameters.
S1P receptors are expressed in atrial cardiac myocytes and vascular endothelium (particularly in the eye).
Initial activation of cardiac S1P receptors causes parasympathetic-like bradycardia, while vascular modulation in the retina can cause fluid extravasation.
3
Select the appropriate clinical tests to monitor these specific risks.
An ECG with a 6-hour observation period evaluates cardiac conduction, and an ophthalmologic exam assesses for macular edema.
These interventions directly mitigate the high-risk, idiosyncratic complications associated with fingolimod initiation.

Anahtar Kavram

Fingolimod initiation requires strict cardiovascular observation (baseline ECG and 6-hour monitoring for bradycardia) and ophthalmologic evaluation (for macular edema) due to its modulation of systemic S1P receptors.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru